Parallax Volatility Advisers
NBIX icon

Parallax Volatility Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Parallax Volatility Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30,100
Closed -$3.39M – 2386
2023
Q3 		$3.39M Buy
+30,100
New +$3.17M 0.01% 908
2021
Q3 		– Sell
-4,600
Closed -$447K – 2072
2021
Q2 		$447K Sell
4,600
-43,100
-90% -$4.13M ﹤0.01% 1177
2021
Q1 		$4.64M Buy
47,700
+43,100
+937% +$4.52M 0.01% 528
2020
Q4 		$441K Buy
4,600
+4,500
+4,500% +$435K ﹤0.01% 1693
2020
Q3 		$10K Sell
100
-1,300
-93% -$150K ﹤0.01% 2972
2020
Q2 		$170K Buy
+1,400
New +$155K ﹤0.01% 2268
2019
Q1 		– Sell
-100
Closed -$7K – 3581
2018
Q4 		$7K Buy
+100
New +$9.58K ﹤0.01% 2545
2018
Q1 		– Sell
-30,000
Closed -$2.33M – 3549
2017
Q4 		$2.33M Buy
+30,000
New +$2.05M ﹤0.01% 877
2017
Q2 		– Sell
-22,400
Closed -$970K – 3350
2017
Q1 		$970K Buy
+22,400
New +$960K ﹤0.01% 1172
2016
Q2 		– Sell
-20,000
Closed -$791K – 3182
2016
Q1 		$791K Buy
+20,000
New +$794K ﹤0.01% 1282

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parallax Volatility Advisers's NBIX Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 16,173 shares — an estimated $1.72M sold.

Parallax Volatility Advisers first reported a position in NBIX in Q4 2017 and held it in 11 quarters. The position peaked at $2.01M in Q3 2021. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 16,173 Neurocrine Biosciences shares in Q4 2022, an estimated $1.72M.
  • Parallax Volatility Advisers first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 11 quarters.
  • Parallax Volatility Advisers's Neurocrine Biosciences position peaked at $2.01M in Q3 2021.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.